Aprepitant, granisetron, and dexamethasone for prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: Results of a randomized, placebo-controlled phase III Trial

Journal of Clinical Oncology

Volumn 32, Issue 30, 2014, Pages 3413-3420

  Schmitt, Thomas ^a   Goldschmidt, Hartmut ^a   Neben, Kai ^b   Freiberger, Anja ^a   Hüsing, Johannes ^a   Gronkowski, Martina ^a   Thalheimer, Markus ^a   Pelzl, Le Hang ^a   Mikus, Gerd ^a   Burhenne, Jürgen ^a   Ho, Anthony D ^a   Egerer, Gerlinde ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b Klinikum Mittelbaden   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APREPITANT; DEXAMETHASONE; DIMETHYL SULFOXIDE; GRANISETRON; MELPHALAN; PLACEBO; MORPHOLINE DERIVATIVE;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BRAIN DISEASE; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONSTIPATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EDEMA; EVALUATION STUDY; FATIGUE; FEMALE; FOLLOW UP; FUNCTIONAL LIVING INDEX EMESIS; HUMAN; HYPOCALCEMIA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PHASE 3 CLINICAL TRIAL; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; AUTOTRANSPLANTATION; CLINICAL TRIAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; NAUSEA; PSYCHOLOGY; VOMITING;

DEXAMETHASONE; DOUBLE-BLIND METHOD; GRANISETRON; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MELPHALAN; MORPHOLINES; MULTIPLE MYELOMA; NAUSEA; PROSPECTIVE STUDIES; QUALITY OF LIFE; TRANSPLANTATION, AUTOLOGOUS; VOMITING;

EID: 84908400421     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.55.0095     Document Type: Article

References (36)

1. Lindley CM, Hirsch JD, O'Neill CV, et al: Quality of life consequences of chemotherapy-induced emesis. Qual Life Res 1:331-340, 1992
2. Roila F, Herrstedt J, Aapro M, et al: Guideline update for MASCC and ESMO in the prevention of chemotherapy-and radiotherapy-induced nausea and vomiting: Results of the Perugia consensus conference. Ann Oncol 21:v232-v243, 2010 (suppl 5)
3. Basch E, Prestrud AA, Hesketh PJ, et al: Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 29: 4189-4198, 2011
4. Hesketh PJ, Grunberg SM, Gralla RJ, et al: The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A multinational, randomized, double-blind, placebo-controlled trial in patients receiving highdose cisplatin-The Aprepitant Protocol 052 Study Group. J Clin Oncol 21:4112-4119, 2003
5. Schmoll HJ, Aapro MS, Poli-Bigelli S, et al: Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Ann Oncol 17:1000-1006, 2006
6. Warr DG, Hesketh PJ, Gralla RJ, et al: Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol 23:2822-2830, 2005
7. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al: Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, doubleblind, placebo-controlled trial in Latin America. Cancer 97:3090-3098, 2003
8. Fassas AB, Spencer T, Desikan R, et al: Cytotoxic chemotherapy following tandem autotransplants in multiple myeloma patients. Br J Haematol 119:164-168, 2002
9. Goldschmidt H, Sonneveld P, Cremer FW, et al: Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients. Ann Hematol 82:654-659, 2003
10. McElwain TJ, Hedley DW, Gordon MY, et al: High dose melphalan and non-cryopreserved autologous bone marrow treatment of malignant melanoma and neuroblastoma. Exp Hematol 7:360-371, 1979 (suppl 5)
11. Selby PJ, McElwain TJ, Nandi AC, et al: Multiple myeloma treated with high dose intravenous melphalan. Br J Haematol 66:55-62, 1987
12. Stiff PJ, Fox-Geiman MP, Kiley K, et al: Prevention of nausea and vomiting associated with stem cell transplant: Results of a prospective, randomized trial of aprepitant used with highly emetogenic preparative regimens. Biol Blood Marrow Transplant 19:49.e1-55.e1, 2013
13. Martin AR, Pearson JD, Cai B, et al: Assessing the impact of chemotherapy-induced nausea and vomiting on patients' daily lives: A modified version of the Functional Living Index-Emesis (FLIE) with 5-day recall. Support Care Cancer 11:522-527, 2003
14. Schulz KF, Altman DG, Moher D: CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials. PLoS Med 7:e1000251, 2010
15. Gralla RJ, Navari RM, Hesketh PJ, et al: Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy. J Clin Oncol 16:1568-1573, 1998
16. Noble A, Bremer K, Goedhals L, et al: A double-blind, randomised, crossover comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: Assessment of efficacy, safety and patient preference-The Granisetron Study Group. Eur J Cancer 30A:1083-1088, 1994
17. Ondansetron plus dexamethasone versus metoclopramide plus dexamethasone plus diphenhydramine in cisplatin-treated patients with ovarian cancer: Italian Group for Antiemetic Research. Support Care Cancer 2:167-170, 1994
18. Schemper M: Cox analysis of survival data with non-proportional hazard functions. J R Stat Soc 41:455-465, 1992
19. Egerer G, Eisenlohr K, Gronkowski M, et al: The NK receptor antagonist aprepitant does not alter the pharmacokinetics of high-dose melphalan chemotherapy in patients with multiple myeloma. Br J Clin Pharmacol 70:903-907, 2010
20. Bubalo JS, Leis JF, Curtin PT, et al: A randomized, double-blinded, pilot trial of aprepitant added to standard antiemetics during conditioning therapy for hematopoietic stem cell transplant (HSCT). J Clin Oncol 25, 2007 (suppl; abstr 9112)
21. Bubalo JS, Cherala G, McCune JS, et al: Aprepitant pharmacokinetics and assessing the impact of aprepitant on cyclophosphamide metabolism in cancer patients undergoing hematopoietic stem cell transplantation. J Clin Pharmacol 52:586-594, 2012
22. Jordan K, Jahn F, Jahn P, et al: The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (high-dose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): Efficacy and safety of a triple antiemetic combination. Bone Marrow Transplant 46:784-789, 2011
23. Uchida M, Ikesue H, Miyamoto T, et al: Effectiveness and safety of antiemetic aprepitant in Japanese patients receiving high-dose chemotherapy prior to autologous hematopoietic stem cell transplantation. Biol Pharm Bull 36:819-824, 2013
24. Uchida M, Kato K, Ikesue H, et al: Efficacy and safety of aprepitant in allogeneic hematopoietic stem cell transplantation. Pharmacotherapy 33:893-901, 2013
25. Pielichowski W, Barzal J, Gawronski K, et al: A triple-drug combination to prevent nausea and vomiting following BEAM chemotherapy before autologous hematopoietic stem cell transplantation. Transplant Proc 43:3107-3110, 2011
26. Pielichowski W, Gawronski K, Mlot B, et al: Triple drug combination in the prevention of nausea and vomiting following busulfan plus cyclophosphamide chemotherapy before allogeneic hematopoietic stem cell transplantation. J BUON 16:541-546, 2011
27. Paul B, Trovato JA, Thompson J, et al: Efficacy of aprepitant in patients receiving high-dose chemotherapy with hematopoietic stem cell support. J Oncol Pharm Pract 16:45-51, 2010
28. Deauna-Limayo D, Aljitawi OS, Ganguly S, et al: Combined use of multiday palonosetron with aprepitant and low-dose dexamethasone in prevention of nausea and emesis among patients with multiple myeloma and lymphoma undergoing autologous hematopoietic stem cell transplant: A pilot study. J Oncol Pharm Pract 20:263-269, 2013
29. Murakami M, Hashimoto H, Yamaguchi K, et al: Effectiveness of palonosetron for preventing delayed chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy in patients with gastrointestinal cancer. Support Care Cancer 22:905-909, 2014
30. Schwartzberg L, Barbour SY, Morrow GR, et al: Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapyinduced nausea and vomiting (CINV). Support Care Cancer 22:469-477, 2014
31. Celio L, Agustoni F, Ricchini F, et al: Palonosetron plus dexamethasone in highly emetogenic chemotherapy: Pooled data from two phase III trials. Future Oncol 9:1451-1458, 2013
32. Navari RM, Gray SE, Kerr AC: Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A randomized phase III trial. J Support Oncol 9:188-195, 2011
33. Mizukami N, Yamauchi M, Koike K, et al: Olanzapine for the prevention of chemotherapyinduced nausea and vomiting in patients receiving highly or moderately emetogenic chemotherapy: A randomized, double-blind, placebo-controlled study. J Pain Symptom Manage 47:542-550, 2014
34. Sekine I, Segawa Y, Kubota K, et al: Risk factors of chemotherapy-induced nausea and vomiting: Index for personalized antiemetic prophylaxis. Cancer Sci 104:711-717, 2013
35. Molassiotis A, Aapro M, Dicato M, et al: Evaluation of risk factors predicting chemotherapyrelated nausea and vomiting: Results from a European prospective observational study. J Pain Symptom Manage 47:839.e4-848.e4, 2014
36. Hesketh PJ, Grunberg SM, Herrstedt J, et al: Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: Effect of gender on treatment response. Support Care Cancer 14:354-360, 2006